Eli Lilly (LLY) CFO says the orforglipron pill could potentially come to the US market as early as Q2 following expected April approval, via Conference

Eli Lilly's CFO indicating that the orforglipron pill could be on the US market as early as Q2, pending April approval, signals a potentially lucrative growth avenue for the company. This could enhance investor sentiment towards Eli Lilly, especially if the expectations around this product are baked into current valuations; thus, monitoring the stock for upward revisions in guidance or analyst ratings would be prudent.